Swift Biosciences Launchs The Accel-NGS PCR-Free DNA Library Kit
11/12/2013 8:49:29 AM
ANN ARBOR, MI – November 11, 2013 -- Swift Biosciences, Inc. today announced the launch of the Accel-NGS™ PCR-free DNA Library Kit for Illumina Next Generation Sequencing (NGS) systems. This launch follows the successful launch earlier this year of a similar product for use on Ion Torrent platforms. Swift’s new kit is designed to bring the same benefits - low input requirement, PCR-free capability and fast, easy workflow - to the Illumina platform.
With the Accel-NGS PCR-free DNA Library Kit for Illumina, scientists can now produce high complexity, PCR-free libraries with as little as 250 ng of input DNA. Libraries have been achieved from even lower inputs (down to 100 ng), but may require library concentration prior to loading the flow cell. High sequence quality and coverage with very low chimera formation are now possible from low DNA input levels.
The Accel-NGS PCR-free DNA Library Kit for Illumina protocol is fast, requiring approximately 90 minutes start-to-finish, and consists of 5 easy steps. In addition, unlike the other library kits on the market, the Accel-NGS PCR-free DNA Library Kit does not require intact double-stranded DNA, making it compatible with damaged samples. Optional single and dual indexing sets are available.
To learn more about how Accel-NGS accelerates NGS library preparation – PCR-free, please visit www.swiftbiosci.com.
About Swift Biosciences
Swift Biosciences is a small, fast-moving company focused on developing innovative enabling technologies for genomics and personalized medicine. With the launch of its line of Accel-NGS products, Swift is now applying its unique technologies to the Next Generation Sequencing market. Swift is working diligently to improve NGS sample preparation, an area that has not kept pace with the significant improvements made recently in NGS instrumentation and bioinformatics.
The company also has products for qPCR detection of mutations. Swift’s first products, launched in 2012, are based on myT® Primer technology which provides both high sensitivity and specificity in somatic mutation detection, making it ideal for cancer research and diagnostic applications. To date, Swift has developed myT Primers for common mutations in the BRAF and KRAS genes, which demonstrate the superior performance capabilities of the technology. Additional myT Primer reagents will be launched in the near future.
In December of 2012, Swift granted a non-exclusive license for myT Primers to an international diagnostics company. Swift will continue to develop myT Primers for RUO applications as well as license to other partners. To facilitate licensing by additional partners, Swift recently introduced a Technology Access Program for myT Primers.
Chief Commercial Officer
Swift Biosciences, Inc.
58 Parkland Plaza
Ann Arbor, MI 48103
Help employers find you! Check out all the jobs and post your resume.